Bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb), is approved, based on a high level of evidence, as first-line therapy for metastatic nonsquamous NSCLC in several countries around the world [3–7]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.